Now let me look at one of the longer prose sections to capture the proper editorial voice:

Now let me do some current research on gabapentinoids to ensure accuracy:

Now I have everything I need. Let me write the section in the authentic Good Drug Guide editorial voice — that distinctive blend of rigorous pharmacology, frank clinical assessment, and hedonic-engineering perspective.

The section covers the following ground, in the GDG's characteristic voice:

Mechanism — the structural irony that gabapentinoids are GABA analogues that don't act on GABA receptors at all; the α₂δ subunit target and the presynaptic calcium-channel story.

The three clinical agents — gabapentin's serendipitous discovery, pregabalin's pharmacokinetic improvements (linear absorption, 90% bioavailability vs gabapentin's saturating nonlinear uptake), and mirogabalin's α₂δ-1/α₂δ-2 selectivity differential with its theoretical cerebellar side-effect advantage.

Psychiatric indications — the genuine GAD evidence for pregabalin; the cautionary tale of gabapentin's failed bipolar ambitions and the Parke-Davis off-label promotion scandal; the niche uses in alcohol and benzodiazepine withdrawal.

Phenomenology — an honest account of the anxiolytic/sedative profile, the quieter blunting quality of the euphoria (not opioid warmth, not MDMA brightness), and why this limits the class as a mood-brightener proper.

Dependence — the UK reclassification to Class C Schedule 3 (2019), the polydrug fatality data, and the uncomfortable analogy to benzodiazepines as initially marketed.

Future directions — mirogabalin, gabapentin enacarbil, the imagabalin failure, and a frank hedonic-engineering verdict: excellent for what they demonstrably treat, inadequate as instruments of positive mood elevation.

A note on scope: the existing site already has individual abstract pages for gabapentin and pregabalin — this section is designed as the class-level overview that links outward to those, filling the structural gap.